

RESEARCH ARTICLE

Non-antibiotic medication use in an Indonesian community cohort 0–18 months of age

Jarir At Thobari^{1,2,3*}, Cahya Dewi Satria^{2,3}, Yohanes Ridora², Emma Watts⁴, Amanda Handley^{4,5}, Jane Standish^{4,6}, Novilia S. Bachtiar⁷, Jim P. Buttery^{4,8,9,10,11}, Yati Soenarto^{2,3}, Julie E. Bines^{4,8,12}

1 Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Special Region of Yogyakarta, Indonesia, **2** Pediatric Research Office, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Special Region of Yogyakarta, Indonesia, **3** Department of Paediatrics, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Special Region of Yogyakarta, Indonesia, **4** RV3 Rotavirus Vaccine Program, Murdoch Children's Research Institute, Parkville, Victoria, Australia, **5** Medicines Development for Global Health, Melbourne, Victoria, Australia, **6** Department of General Medicine, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia, **7** PT Bio Farma, Bandung, West Java, Indonesia, **8** Department of Pediatrics, University of Melbourne, Melbourne, Victoria, Australia, **9** Department of Paediatrics, Monash University, Clayton, Victoria, Australia, **10** School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia, **11** Department of Infection and Immunity, Monash Children's Hospital, Clayton, Victoria, Australia, **12** Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

* j.atthobari@ugm.ac.id



OPEN ACCESS

Citation: At Thobari J, Satria CD, Ridora Y, Watts E, Handley A, Standish J, et al. (2020) Non-antibiotic medication use in an Indonesian community cohort 0–18 months of age. PLoS ONE 15(11): e0242410. <https://doi.org/10.1371/journal.pone.0242410>

Editor: Emma Link, Peter MacCallum Cancer Centre, AUSTRALIA

Received: September 23, 2019

Accepted: October 30, 2020

Published: November 18, 2020

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0242410>

Copyright: © 2020 At Thobari et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its [Supporting Information](#) files.

Abstract

Background

Rational medication use for treatment is mandatory, particularly in children as they are vulnerable to possible hazards of drugs. Understanding the medication use pattern is of importance to identify the problems of drug therapy and to improve the appropriate use of medication among this population.

Methods

A post-hoc study of the RV3-BB Phase IIb trial to children aged 0–18 months which was conducted in Indonesia during January 2013 to July 2016. Any concomitant medication use and health events among 1621 trial participants during the 18 months of follow-up were documented. Information on medication use included the frequency, formulation, indication, duration of usage, number of regimens, medication types, and therapeutic classes.

Results

The majority of participants (N = 1333/1621; 82.2%) used at least one non-antibiotic medication for treatment during the 18-month observation period. A total of 7586 medication uses were recorded, mostly in oral formulation (90.5%). Of all illnesses recorded, 24.7% were treated with a single drug regimen of non-antibiotic medication. The most common therapeutic classes used were analgesics/antipyretics (30.1%), antihistamines for systemic use

Funding: The vaccine company PT Bio Farma provided support for this study in the form of a salary for the author NSB. The specific role of this author is articulated in the 'author contributions' section. Additionally, PT Biofarma was one of the funders of the RV3-BB Phase IIb trial. Another funding source of the RV3-BB Phase IIb trial was Murdoch Children's Research Institute. The funders had roles in the study design, decision to publish, and preparation of the manuscript.

Competing interests: The authors have the following interests: NSB is a paid employee of PT Biofarma. PT Biofarma is a state-owned company (owned by Indonesia government) that provides all vaccines for Indonesia National Immunization Program. Additionally, PT Biofarma was one of the non-commercial funders for the RV3-BB Phase IIb trial. No consultation was done to the funder relating to the trial. The trial was a phase IIb trial and while the RV3-BB rotavirus vaccine is not yet marketed, this vaccine is being developed with the intention for eventual usage in the national immunization program. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

(17.4%), cough and cold preparations (13.5%), vitamins (8.6%), and antidiarrheals (6.6%). The main medication types used were paracetamol (29.9%), chlorpheniramine (16.8%), guaifenesin (8.9%), zinc (4.6%), and ambroxol (4.1%). Respiratory system disorder was the most common reason for medication use (51.9%), followed by gastrointestinal disorders (19.2%), pyrexia (16.9%), and skin disorders (7.0%).

Conclusion

A large number of children were exposed to at least one medication during their early life, including those where evidence of efficacy and safety in a pediatric population is lacking. This supports the need for further research on pediatric drug therapy to improve the appropriate use of medication in this population.

Introduction

Rational and judicious use of medicines is necessary at all ages, and critical in childhood where pre-clinical safety and efficacy data is more limited. In children, this importance of rational drug use is also compounded since they are vulnerable to possible hazards of drugs [1,2]. Several studies showed that off-label and contraindicated drug use for this age are still a major problem [3–6]. A study focusing on drug prescriptions among children at a community pharmacy located in South Jakarta, Indonesia, concluded that polypharmacy, inappropriate dose, and potential drug interactions were still a major problem in that setting [7]. Many drugs exhibit different pharmacokinetic, pharmacodynamic, efficacy and safety effects between children and adults [1,2,8,9]. Therefore, one of the solutions to improve rational use of drugs in children is by understanding the medication use profile among this population [10].

Several studies have been conducted regarding medicine use in children, including those conducted in the early 2000s [1,10–17]. Most of the studies analyzed drug prescriptions from healthcare settings, including pediatric wards, outpatient clinics, or community pharmacies. A more recent study [11] provided an overview of drug use in children in three European countries, suggesting that children less than 2 years old had the highest prescription rate in all three study countries. In Indonesia, information regarding the drug use profile in young children is insufficient. This study is a *post-hoc* analysis of a phase IIb trial of rotavirus vaccine in infants 0–18 months of age in Indonesia which analyzed all non-antibiotic medications used by the trial participants during the study. Antibiotic use in the same trial participants has been described previously [18].

Method

Study design

This study used secondary data from a phase IIb randomized, double-blinded, controlled trial for RV3-BB rotavirus vaccine (Australian New Zealand Clinical Trials Registry number ACTRN12612001282875; the protocol is available at [NEJM.org](https://www.clinicaltrials.gov/ct2/show/study/ACTRN12612001282875)). The RV3-BB phase IIb trial was conducted primarily to evaluate the efficacy of RV3-BB vaccine against severe rotavirus gastroenteritis in children aged up to 18 months. The complete study design of RV3-BB phase IIb trial has been described previously [19] and is briefly summarized here.

Participants

The RV3-BB phase IIb trial was conducted from January 2013 to July 2016 in *Puskesmas*/primary health centers (PHCs) and hospitals in two provinces, Central Java and Yogyakarta, in Indonesia. The trial involved a total of 1649 participants, and 1621 of them gave consent for their information to be used in future studies (Fig 1). Only 49 of 1621 participants (3%) were not completely followed until 18 months. Some of these participants used at least one non-antibiotic medication before being lost to follow-up, therefore we still included these 49 participants in the analysis.

Twenty-three PHCs and two hospitals in Sleman district (an urban area in Yogyakarta province) and Klaten district (a rural area in Central Java province) participated as study sites. After obtaining written informed consents from participants' mothers during pregnancy, healthy neonates were then enrolled in this study up to 6 days of age. The key inclusion criteria were neonates who were healthy, born full-term, and weighed between 2500 and 4000 grams.




Fig 1. Flow diagram of participant follow-up.

<https://doi.org/10.1371/journal.pone.0242410.g001>

Interventions, randomization and blinding

Eligible participants were assigned to one of the three intervention groups (1:1:1): neonatal-schedule vaccine group, infant-schedule vaccine group, and placebo group. Each vaccine group received 3 doses of RV3-BB vaccine and 1 dose of placebo according to their assigned schedule, while the placebo group received 4 doses of placebo only. The 4 doses of vaccine or placebo were administered as the following schedule: dose 1 at 0–5 days of age, dose 2 at 8–10 weeks of age, dose 3 at 14–16 weeks of age, and dose 4 at 18–20 weeks of age. In neonatal schedule, the RV3-BB vaccines were administered at dose 1, 2, and 3, and followed by placebo at dose 4. In infant schedule, the placebo was administered at dose 1, and followed by RV3-BB vaccine at dose 2, 3, and 4.

The trial-group assignment was performed randomly by using a computer-generated code with a block size of 6, stratified by province. All investigators, trial monitors, data managers, other trial staff and participants' families were masked to the trial-group assignment until the end of the study. Only the pharmacist at the central pharmacy in each province who dispensed the RV3-BB vaccine or placebo was aware of the trial-group assignments.

Sample size

The detailed sample size calculation has been described previously [19]. Briefly, our calculation generated an enrollment target of 549 participants in each of the three trial groups. This calculation was based on a power of 80% to reject the null hypothesis of no difference between the combined vaccine group and the placebo group, with an assumption of 3% of the placebo group would have a severe rotavirus gastroenteritis, and the true efficacy of the vaccine was 60% at one-sided alpha level of 0.1. With this sample size, the allowance for nonadherence rate to the trial protocol was 10%.

Concomitant medication and reasons for the usage

During the trial, prospective surveillance of concomitant medication and adverse events (AE) was performed. Concomitant medication was defined as all medications used by the participants to treat AE, excluding antibiotics (has been published previously [18]). Drugs used to prevent an illness (prophylaxis), including vitamin K injection to all newborns after delivery and antipyretics given by the caregiver after immunization without pre-existing fever were also excluded. Medication types and therapeutic classes were classified on the basis of the WHO Anatomical Therapeutic Chemical (ATC). AE episodes were defined as all illnesses or symptoms developed during the 18 months observation period after the first dose of RV3-BB vaccine or placebo. AE episodes were classified using Medical Dictionary for Regulatory Activities (MedDRA) and further narrowed down by the researchers to 12 disorders mainly according to their affected organ systems.

Research assistants made weekly phone calls to ask the mothers about participants' conditions (including AE and concomitant medication use), and participants were visited by study midwives every month for monitoring medications used by participants during the study. Both prescribed and non-prescribed medications were taken into account in the analysis of this study. If the illness or medication use was derived from healthcare visit or hospitalization, information regarding the illness or medication was extracted from their medical record.

Collected information regarding medication use included: type of drug and its therapeutic class, duration of medication use per child, drug formulation (e.g. oral (pulveres, syrup), topical, intravenous, inhalation, rectal or intratracheal), whether the medication was from outpatient or inpatient, and treatment indication. Pulveres is an oral drug formulation containing medicines all ground together and has been used for a long time in Indonesia. Number of

non-antibiotic drug regimen, which was defined as the number of different non-antibiotic medications that were used concurrently from the same start date to treat an illness, was also recorded. Concurrent use of a non-antibiotic medication with antibiotics was considered a single drug regimen in this study. Antibiotic use in RV3-BB trial participants has been described previously [18].

Ethical considerations

This study was approved by Medical and Health Research Ethics Committee of Faculty of Medicine Universitas Gadjah Mada–Dr Sardjito General Hospital. Written informed consent was obtained from the every child's parent or guardian for the RV3-BB phase IIb trial. The subjects included in this post-hoc analysis were those who gave consent for their data to be used in future studies.

Statistical analysis

Statistical calculations were performed by using SPSS version 23. For descriptive data, the results were presented as mean, median, frequency and percentages. Relationships between gender and vaccination group with medication use were assessed with bivariate chi-square. A logistic regression was performed to explore the relationship between the reason of medication use, drug formulation, outpatient/inpatient setting and the age of participant when using the medication with the number of non-antibiotic drug regimen.

Result

Baseline characteristics

Overall, 1333 of 1621 (82.2%) trial participants used at least one non-antibiotic medication during 18-month observation period. The incidence of medication use is similar between males and females, and across intervention groups. Baseline characteristics are summarized in [Table 1](#).

The pattern of medication use

Following exclusion of antimicrobial exposures, a total of 7586 medications were used by 1333 children, with a mean (SD) of 5.69 (4.80) drugs/child. The most common drug route of administration was oral, and most of the medications were used in ambulatory setting ([Table 2](#)). Average use of non-antibiotic medications per AE was 1.72 (SD±0.99). Moreover, 24.7% of all AE were treated with a single drug regimen of a non-antibiotic medication ([Table 3](#)).

The most common age for our participants to be exposed to their first non-antibiotic medication was between 1–6 months old (N = 1083/1333; 81.2%), followed by 0–1 month (N = 229/1333; 17.2%), 6–12 months (N = 18/1333; 1.2%), and only 0.2% (N = 3/1333) had their first non-antibiotic medication between 12–18 months of age.

Table 1. Baseline characteristics of study participants with non-antibiotic medication use.

Characteristics	All (n = 1621)	Medication use (n = 1333)	No medication use (n = 288)	p-value	RR
Gender (%)					
Male	844 (52.1)	699 (82.8)	145 (17.2)	0.52	1.02 (0.97–1.06)
Female	777 (47.9)	634 (81.6)	143 (18.4)	Ref	Ref
Vaccination group (%)					
Neonates	541 (33.4)	450 (83.2)	91 (16.8)	0.88	1.00 (0.95–1.06)
Infants	538 (33.2)	434 (80.7)	104 (19.3)	0.36	0.97 (0.92–1.03)
Placebo	542 (33.4)	449 (82.8)	93 (17.2)	Ref	Ref

<https://doi.org/10.1371/journal.pone.0242410.t001>

Table 2. The pattern of medication use in children.

Pattern indicator (N = 7586)	Results
Drug formulation (%)	
Oral formulation	6865 (90.5)
Pulveres	4722 (62.3)
Syrup/drop	1651 (21.8)
Oral solution	149 (1.9)
Unknown oral	343 (4.5)
Topical	513 (6.8)
Skin preparation	512 (6.8)
Ear preparation	1 (0.01)
Other	208 (2.7)
Intravenous	85 (1.1)
Inhalation	67 (0.9)
Rectal	55 (0.7)
Intratracheal	1 (0.01)
Outpatient/inpatient medication use (%)	
Outpatient	7076 (93.3)
Inpatient	510 (6.7)
Duration of drug use per child (days) [median (min-max)]	3.67 (1–63)

<https://doi.org/10.1371/journal.pone.0242410.t002>

Factors associated with the number of non-antibiotic medication used per AE

A logistic regression was done to explore the relationship between gender, patient care setting, reasons for medication use, age on medication use, and route of administrations with the number of non-antibiotic medication used per AE (Table 4). Gender was the only factor that was not significantly associated with the number of medications used. Oral route administration (RR = 3.14; 95% CI = 2.12–4.65) and having respiratory disorders, gastrointestinal disorders, and unspecified pyrexia as the reasons for medication use (RR = 3.07; 95% CI = 2.18–4.32) had the highest RRs. Using medication at an age of older than 4 months was also associated with a higher number of medications used per AE (RR = 1.57; 95% CI = 1.35–1.81), as well as in inpatient care setting (RR = 1.38; 95% CI = 1.02–1.87).

Drug classes

The ten most commonly used therapeutic classes in this study covered 98.6% of all treated infants, and 93.1% of all medications used. The largest therapeutic class used was analgesics/antipyretics, comprising 30.1% of all medications used, and overwhelmingly as paracetamol (N = 2268/2280; 99.5%). Extremely rare metamizole and ibuprofen utilizations were noted in

Table 3. Number of non-antibiotic drug regimen.

Non-antibiotic drug regimen	No. of children (N(%))*	Adverse events (N(%))*
Single	1143 (85.8)	2400 (24.7)
Double	572 (42.9)	822 (8.5)
Triple	508 (38.1)	1437 (14.8)
More than triple	207 (15.5)	906 (9.3)

*During the trial, a child could have more than one episode of treatment and adverse event

<https://doi.org/10.1371/journal.pone.0242410.t003>

Table 4. Factors associated with the number of non-antibiotic medication used per AE.

Factors	Use of ≥ 3 non-antibiotic medications per AE [N (%)]	Use of ≤ 2 non-antibiotic medications per AE [N(%)]	Adjusted RR* (95% CI)
Gender			
Male (N = 2415)	545 (22.6)	1870 (77.4)	1.06 (0.92–1.23)
Female (N = 1993)	438 (22.0)	1555 (78.0)	Ref
Patient care setting			
Inpatient (N = 277)	67 (24.2)	210 (75.8)	1.38 (1.02–1.87)
Outpatient (N = 4131)	916 (22.2)	3215 (77.8)	Ref
Reasons for medication use**			
Respiratory disorders, gastrointestinal disorders, and unspecified pyrexia (N = 3699)	939 (25.4)	2760 (74.6)	3.07 (2.18–4.32)
Other indications (N = 709)	44 (6.2)	665 (93.8)	Ref
Age on medication use**			
>4 months (N = 1919)	534 (27.8)	1385 (72.2)	1.57 (1.35–1.81)
≤ 4 months (N = 2489)	449 (18.0)	2040 (82.0)	Ref
Route of administration			
Oral (N = 3802)	950 (25.0)	2852 (75.0)	3.14 (2.12–4.65)
Other routes (N = 606)	33 (5.4)	573 (94.6)	Ref

Note: During the trial, a child could have more than one episode of adverse event. Only adverse events that treated with non-antibiotic medications are included in the table.

*Relative risk was adjusted for gender, patient care setting, reasons for medication use, age on medication use, and route of administration.

**Respiratory disorders, gastrointestinal disorders and unspecified pyrexia are the largest reasons for medication use.

**The mean age on medication use was 4.0 ± 2.7 months.

<https://doi.org/10.1371/journal.pone.0242410.t004>

this study (N = 8/2280 and 4/2280, respectively). Other main therapeutic classes were also noted, including: antihistamines for systemic use (mainly chlorpheniramine (N = 1275/1316; 96.9%)), cough and cold preparations (guaifenesin (N = 677/1020; 66.4%); ambroxol (N = 311/1020; 30.5%)), vitamins (ascorbic acid (N = 227/652, 34.8%); vitamin B6 (N = 185/652; 28.4%)), and antidiarrheals (oral rehydration salt formulations (N = 255/502; 50.8%); probiotics (N = 130/502; 25.9%)). These results can be seen in Tables 5 and 6.

Reasons for using medication

Of all participants, 93.6% (N = 1518/1621) experienced at least one AE during the observation period. Moreover, the first AE of each participant was commonly occurred between 1–6 months old (N = 825/1518; 54.3%), followed by 0–1 months (N = 678/1518; 44.7%), 6–12 months (N = 9/1518; 0.6%), and rarely in 12–18 months old (N = 6/1518; 0.4%).

Respiratory illness, gastrointestinal illness, pyrexia and skin disorders were the most common reasons for the participants to take non-antibiotic medication during the study (95.1%). The largest therapeutic classes used for treating respiratory system disorders were antihistamines for systemic use, cough and cold preparations, analgesics/antipyretics, vitamins, and drugs for obstructive airway. For gastrointestinal disorders, the main therapeutic classes were antidiarrheals, mineral supplements, analgesics/antipyretics, vitamins, and drugs for acid related disorders. Analgesics/antipyretics was the most commonly used medication for pyrexia (91.2%). Among medications for skin disorders, corticosteroids in dermatological preparations was the largest therapeutic class used by our participants, followed by emollients-and-protectives, antihistamines for systemic use, antifungals for dermatological use, and antiseptics-and-disinfectants. Although vitamins appeared to be used in many types of AE, they were

Table 5. Fifteen main therapeutic classes used in participants.

No.	Medication classes	ATC Code	No. of drug use (%)	No. of participants	Prevalence rate (per 100 participants)
1	Analgesics/antipyretics	N02	2280 (30.1)	1093	67.4
2	Antihistamines for systemic use	R06	1316 (17.4)	772	47.6
3	Cough and cold preparations	R05	1020 (13.5)	614	37.9
4	Vitamins	A11	652 (8.6)	411	25.4
5	Antidiarrheals and intestinal antiinflammatory agents	A07	502 (6.6)	312	19.3
6	Mineral supplements	A12	490 (6.5)	325	20.1
7	Bronchodilators	R03	287 (3.8)	185	11.4
8	Corticosteroids, dermatological preparations (topical agents)	D07	189 (2.5)	156	9.6
9	Nasal preparations	R01	178 (2.4)	150	9.3
10	Emollients and protectives	D02	145 (1.9)	123	7.6
11	Drugs for acid related disorders	A02	80 (1.1)	69	4.3
12	Drug for constipation	A06	52 (0.7)	40	2.5
13	Corticosteroids for systemic use	H02	46 (0.6)	38	2.3
14	Antiseptics and disinfectants (topical agents)	D08	41 (0.5)	41	2.5
15	Antifungals for dermatological use	D01	38 (0.1)	36	2.2
	Total		7586 (100)	1621 (100)	

*See S1 Table. All of non-antibiotic therapeutic classes used by trial participants during study period

<https://doi.org/10.1371/journal.pone.0242410.t005>

mainly used in respiratory system disorders (N = 452/652; 69.3%). We also noted that lymphatic system disorder appeared as if it was not treated with any drugs, however, it was completely treated with antibiotic as monotherapy which was not taken into account in this study. These results were summarized in Figs 2 and 3. Moreover, all adverse events episodes recorded during the study are presented in Table 7.

Table 6. Fifteen main medications used in participants.

No	Type of drug	ATC Code	No. of drug use (%)	No. of participants	Prevalence rate (per 100 participants)
1	Paracetamol	N02BE01	2268 (29.9)	1093	67.4
2	Chlorpheniramine	R06AB04	1275 (16.8)	753	46.5
3	Guaifenesin	R05CA03	677 (8.9)	465	28.7
4	Zinc	A12CB01	414 (4.6)	294	18.1
5	Ambroxol	R05CB06	311 (4.1)	226	13.9
6	Salbutamol	R03CC02	273 (3.6)	181	11.2
7	Oral rehydration salt formulations	A07CA	255 (3.4)	193	11.9
8	Ascorbic acid (Vitamin C)	A11GA01	227 (3.0)	179	11.0
9	Vitamin B6	A11HA02	185 (2.4)	140	8.6
10	Probiotics	A07FA51	130 (1.7)	110	6.8
11	Hydrocortisone	D07AA02	127 (1.7)	112	6.9
12	Dexamethasone	H02AB02	117 (1.5)	97	6.0
13	Calcium	A12AA05	79 (1.0)	55	3.4
14	Other emollients and protectives	D02AX	73 (1.0)	64	4.0
15	Ordinary salt combinations	A02AD01	70 (0.9)	62	3.8
	Total		7586 (100)	1621 (100)	

*See S2 Table. All of non-antibiotic medications used by trial participants during study period

<https://doi.org/10.1371/journal.pone.0242410.t006>




Fig 2. Reasons for non-antibiotic medication use. Each participant could contribute multiple times to each reason.

<https://doi.org/10.1371/journal.pone.0242410.g002>

Discussion

Non-antibiotic medication use pattern

The majority of our trial participants (82.2%) used at least one medication during the 18-month of follow up. This number is comparable with similar previous studies held in Sweden [20], which suggested that: in the first year of life, 71% of the infants had at least one




Fig 3. Five main therapeutic classes used based on the reason for non-antibiotic medication use. Each participant could contribute multiple times to each therapeutic class.

<https://doi.org/10.1371/journal.pone.0242410.g003>

medication use. The number of participants using medication is similar across genders. However, other studies found different results. While a study noted that males received more drug prescriptions than females at all ages (0–14 years), some other studies showed that males only predominated at younger ages, especially in ≤ 10 years old, and females predominated in older children [1,17,21]. The reason for different results are difficult to determine, but most possibly due to different extent of diseases, caregiver knowledge, or local practice.

This study also did not show a reduction in the incidence of medication use in the vaccinated groups. This partly reflects that, although RV3-BB rotavirus vaccine efficacy against severe rotavirus gastroenteritis has been well established [19], it did not prevent all illnesses or medication uses. As far as we know, there have been no reports on the reduction of all medication use in children following any type of vaccinations. This is most likely due to a wide range of disease other than the illness targeted by the vaccine that could encourage children to use medication.

The most common age for our participants to be exposed to their first non-antibiotic medication was between 1–6 months old (81.2%), and followed by 0–1 month old (17.2%). A similar order of age groups was also observed in terms of the occurrence of the first adverse event. Therefore, it can be said that it is a common practice in Indonesia to expose a child at a very young age (under 6 months old) to a non-antibiotic medication once they start to get ill.

Table 7. Adverse event episodes recorded during the study period.

	Adverse event	Participants (N (%))	Total episodes of adverse event (N)	% (SE)	Episodes of AE treated by non-antibiotic medications (N)	% (SE)
1	Respiratory system disorders	995 (65.6)	1854	19.1 (0.40)	1402	75.6 (1.00)
2	Unspecified pyrexia	935 (61.6)	1587	16.4 (0.38)	1142	71.9 (1.13)
3	Skin disorders	408 (26.9)	550	5.7 (0.24)	355	64.6 (2.04)
4	Metabolism and nutrition disorders	29 (1.9)	30	0.3 (0.06)	12	40 (8.94)
5	Ear disorders	23 (1.5)	25	0.3 (0.06)	10	40 (9.80)
6	Other infections	95 (6.3)	101	1.0 (0.1)	31	30.7 (4.59)
7	Gastrointestinal disorders	985 (64.9)	2335	24.1 (0.43)	697	29.9 (0.95)
8	Genitourinary disorders	39 (2.6)	43	0.4 (0.06)	11	25.6 (6.66)
9	Central-peripheral nervous system	55 (3.6)	60	0.6 (0.08)	15	25 (5.59)
10	Ocular disorders	88 (5.8)	95	0.9 (0.1)	5	5.3 (2.3)
11	Lymphatic system disorders	3 (0.2)	3	0.1 (0.03)	0	0 (0)
12	Other disorders	942 (62.1)	3026	31.2 (0.47)	148	4.9 (0.39)
	Total	1518 (100)	9709	100	3849	39.6 (5)

The table included only participants who had at least one AE during the 18 months of follow-up (N = 1518/1621). The list is ordered by the proportion of adverse event (AE) episodes treated with non-antibiotic medications. SE: Standard Error of proportion

<https://doi.org/10.1371/journal.pone.0242410.t007>

Formulation and duration

The predominance of oral drug formulation in our study (90.5%) was also seen in other previous similar studies [10,13,22,23]. Oral liquid formulations are widely used among young children since they are easier to swallow than the solid form [24]. However, in this study, pulveres was the most commonly used oral formulation. Pulveres is frequently used in Indonesia, especially for their lower price and flexibility to accommodate drug combinations. This may explain why oral formulation is associated with higher number of drug regimen in this study (Table 4). Considering this advantage, prescribers should be aware of any potential drug interactions when prescribing drug combination in their practice [25,26]. Rectal, inhalation, and injections were less frequently used in this study, and also in other studies [10,13,22,23]. Median duration of medication use per child in this study was 3.67 days (ranged between 1 to 63 days). However, by far, there have been no studies focusing on overall duration of medication use in infants.

Number of and factors associated with non-antibiotic drug regimen

The average number of non-antibiotic drug regimens used was 1.72 ± 0.99 drugs per regimen. Moreover, a quarter of all AE were treated with a single drug regimen of non-antibiotic medication (Table 3). This result was lower than previous studies focusing on drug prescriptions in wider range of age population (≤ 12 years of age [27]; ≤ 5 years of age [13]) showing the average of 2.5–2.6 drugs per prescription, respectively. Fewer number of drugs per regimen in our study might be due to the younger age of population using medication which tend to have a single clinical condition, thus impact on the fewer number of medication needed [10]. This also explains a consumption of higher number of drugs by older infants (Table 4). The inclusion of prescription and non prescription drugs and the exclusion of antibiotics in our study also might affect the average number of drug regimen compared to those who calculated prescribed drugs only without excluding antibiotic, as non-prescribed drug tend to be used in milder conditions that need fewer number of drug per regimen.

Reasons for medication use (respiratory disorders, gastrointestinal disorders, unspecified pyrexia), participant's age older than 4 months when using the medication, oral drug formulation and inpatient care setting were strongly associated with the number of non-antibiotic drug regimen. Respiratory disorders, gastrointestinal disorders, and unspecified pyrexia manifest as multiple symptoms thus may encourage child caretakers to self-medicate the children with multiple over-the-counter (OTC) [10,22]. Hospitalized child may also indicate a more complex diagnosis to be treated, thus more medications may be required [10].

The most common therapeutic classes and the reasons for usage

The ten most commonly used therapeutic classes in this study accounted for 93.1% of all medications used by participants. A similar result was also noted in previous study which showed that the 10 most prescribed therapeutic classes in 0–1 years old children accounted for 92.7% of all drugs used [17]. Five out of those ten main therapeutic classes were similar with our study (analgesics, emollient, dermatological corticosteroid, nasal preparation, and cough and cold preparations). Similar to other studies, respiratory system disorder was the primary indication for medication use in our study [10,17,22,28].

The results of this study might represent the non-antibiotic medication use in wider population of young children in Yogyakarta and Central Java provinces in Indonesia, considering the large sample size used in the study.

Analgesics/antipyretics. Analgesics/antipyretics were the most commonly used therapeutic classes in this study, accounting for 30.1% of all drugs consumed, overwhelmingly as

paracetamol (99.5%), and used by 67.4% of all participants. This drug usage pattern was similar to other studies [1,10,17,23]. However, although ibuprofen and metamizole were rarely used by our participants (N = 4/7586 and N = 8/7586, respectively), both were the most frequently prescribed drugs among 0–18 years old children admitted to pediatric ward in Germany (8.9% and 8.6%, respectively) [10]. The reasons for different results were difficult to determine, but possible explanations might be due to the younger age of participants in our study, and the difference therapeutic practices, local drugs availability, or treatment guidelines [10]. Both paracetamol and ibuprofen are the recommended antipyretics in children [29,30].

Antihistamines and cough and cold preparations. Antihistamines and cough and cold preparations are the second and third largest therapeutic classes used in this study, with the major reason for their use as respiratory system disorders (N = 1148/1316; 87.2% and N = 1002/1020; 98.2%, respectively). These results likely reflect the fact that these are main ingredients of widely available cough and cold medications (CCMs). However, there is no good evidence of over-the-counter CCMs, such as antihistamines, decongestants, antitussives and expectorants, being superior to placebo against acute cough in young children, according to a review of pertinent trials [31] and the use of OTC CCMs in children under 6 years old were also not recommended [32–35].

Half of our participants used at least one systemic antihistamine during their first 18 month of life, which is higher compared to other studies showing 31% of 4511 children had used antihistamines by the age of 2 years in the Netherlands [1], and 17% of 1701 children during the first 5 years of life in Sweden [20]. Cough and cold preparations use in the first 18 months of life were also more frequent in our study (37.88%) than in another study in Netherlands (16%) [1]. This might partly reflect a higher incidence of respiratory tract infections in our population.

Antihistamines have been widely used for decades in clinical practice to treat hyperhistaminic conditions. However, in a meta-analysis of 35 studies focusing on antihistamine use for treating URTIs in adults and children found that there was no clinically significant effect [36]. Moreover, first-generation antihistamines (e.g. chlorpheniramine) were frequently associated with non-serious adverse effect particularly sedation, and such adverse effect might disturb patient's performance of routine tasks, particularly in older children [37].

Some studies reported child deaths associated with self-medication of CCMs, which appeared significantly higher in children under 2 years old [38–40]. An expert panel evaluating 103 children death cases involving non-prescribed CCM uses, concluded that five drugs most frequently mentioned as at least possibly related with the deaths were: pseudoephedrine (N = 43.7%), diphenhydramine (N = 36.9%), dextromethorphan (N = 35%), chlorpheniramine (N = 16.5%), and brompheniramine (N = 12.6%). There were no mentions of guaifenesin being related with the deaths according to the evaluation. The panel concluded that deaths after using these drugs were more likely from product misuse rather than their adverse effects of recommended doses [40]. Therefore, education to caregivers about the proper use of cough and cold medication in children, especially aged <2 years old, should be considered to prevent misuse of these drugs.

Vitamins. We noted that almost 10% of all medications used by our participants were vitamins, predominantly ascorbic acid and vitamin B6 (34.8% and 28.4%, respectively). The main reason for administering ascorbic acid and vitamin B6 was for respiratory system disorders (87.7% and 69.3%, respectively). A review of eight RCTs showed that vitamin C intake reduced the duration of URTI by 1.6 days in children [41]. However, the evidence of vitamin B6 efficacy for the treatment or prevention of respiratory system disorders was rarely studied. Possible explanations of the utilization in our study are: (1) parental or prescriber (for prescribed drugs) lack of knowledge of vitamin B6 indication; (2) local supplies of particular

vitamin that occasionally wear out thus substituted with other type of vitamin; (3) local belief that any type of vitamin would improve child's appetite which tend to be decreased due to illness [42]. Although not being investigated in children, vitamin B6 overdose in adult has been known to induce neurotoxic syndrome [43]. Therefore, the exact reason of its utilization should be further evaluated to improve the rational use of this drug in young children.

Antidiarrheals, intestinal antiinflammatory/antiinfective agents. Gastrointestinal disorders were the second most common reason for the participants to take medication, and antidiarrheals were the largest drug class taken, followed by mineral supplements. These results were reasonable as the national and international guideline for management of childhood illnesses recommended the use of oral rehydration salt formulations and zinc as the main therapy for children presenting with diarrhea [44,45]. Probiotics, which was overwhelmingly used for treating gastrointestinal illnesses (98.5%), accounted for a quarter of all antidiarrheal classes used in this study. This is also reasonable as a Cochrane review of 63 studies (56 involved infants and young children) concluded that, probiotics reduced the duration of diarrhea by 25 hours and the risk of diarrhea lasting >4 days by 59% [46]. Moreover, the minimal use of antimotility drugs to treat diarrhea (N = 4/1200; 0.3%) in this study was judicious due to the high rates of side effects among infant and young children, including ileus, respiratory depression, and coma [47].

Conclusion

The majority of children were exposed to at least one medication during their early life. A variety of medications were used, including those where the evidence of efficacy and safety in pediatric population is lacking. This calls for further education to improve caregivers' knowledge on appropriate self-medication in children, and to enhance the guideline compliance by health practitioners to ensure the therapy given to children will be of most benefit.

Supporting information

S1 Checklist. Consort checklist of post-hoc analysis of RV3-BB phase IIb trial.

(DOCX)

S1 Table. Therapeutic classes used by trial participants during study period.

(DOCX)

S2 Table. Type of drugs used by trial participants during study period.

(DOCX)

S1 Dataset.

(XLSX)

Acknowledgments

We would like to express our special gratitude towards the research team of RV3 Rotavirus Vaccine Program from Murdoch Children's Research Institute, Bio Farma, and Pediatric Research Office. We would also like to thank our colleagues from Dr. Sardjito General Hospital (Yogyakarta), Soeradji Tirtonegoro General Hospital (Klaten), Sleman General Hospital (Sleman), and participating PHCs. We also would like to show our gratitude to all project managers, research assistants, study site staff especially the midwives who have monitored the medications received by the participants, and participants' parents in Sleman and Klaten district who have been cooperating in this study. Finally, we would like to acknowledge our colleagues from Sleman and Klaten District Health Office for field research support.

Author Contributions

Conceptualization: Jarir At Thobari, Cahya Dewi Satria, Novilia S. Bachtiar, Jim P. Buttery, Yati Soenarto, Julie E. Bines.

Data curation: Jarir At Thobari, Emma Watts, Amanda Handley, Jane Standish.

Formal analysis: Jarir At Thobari, Yohanes Ridora, Emma Watts, Jane Standish.

Investigation: Jarir At Thobari, Cahya Dewi Satria.

Methodology: Jarir At Thobari, Cahya Dewi Satria, Emma Watts, Amanda Handley, Jane Standish, Novilia S. Bachtiar, Jim P. Buttery, Yati Soenarto, Julie E. Bines.

Project administration: Jarir At Thobari, Cahya Dewi Satria, Emma Watts, Amanda Handley, Jane Standish.

Resources: Novilia S. Bachtiar, Jim P. Buttery, Julie E. Bines.

Supervision: Jim P. Buttery, Yati Soenarto, Julie E. Bines.

Validation: Jarir At Thobari, Emma Watts, Jane Standish, Julie E. Bines.

Writing – original draft: Jarir At Thobari, Yohanes Ridora, Emma Watts, Jim P. Buttery.

Writing – review & editing: Novilia S. Bachtiar, Jim P. Buttery, Yati Soenarto, Julie E. Bines.

References

1. Schirm E, Van den Berg P, Gebben H, Sauer P, De Jong-van den Berg L. Drug use of children in the community assessed through pharmacy dispensing data. *Br J Clin Pharmacol*. 2000; 50(5):473–8. <https://doi.org/10.1046/j.1365-2125.2000.00275.x> PMID: 11069442
2. Ferro A. Paediatric prescribing: why children are not small adults. *Br J Clin Pharmacol*. 2015; 79(3):351–3. <https://doi.org/10.1111/bcp.12540> PMID: 25371355
3. Cheung K, Teichert M, Moll HA, Stricker BH, Visser LE. Filled prescriptions of age-related contraindicated drugs in children: a one-year nationwide cohort study in the Netherlands. *Int J Clin Pharm [Internet]*. 2018; 40(5):1137–43.
4. Wimmer S, Neubert A, Rascher W. The Safety of Drug Therapy in Children. *Dtsch Aerzteblatt Online*. 2015; 112:781–7. <https://doi.org/10.3238/arztebl.2015.0781> PMID: 26806565
5. Luedtke KE, Buck ML. Evaluation of Off-label Prescribing at a Children's Rehabilitation Center. *J Paediatr Pharmacol Ther*. 2014; 19(4):296–301.
6. Czarniak P, Bint L, Favié L, Parsons R, Hughes J, Sunderland B. Clinical setting influences off-label and unlicensed prescribing in a paediatric teaching hospital. *PLoS One*. 2015; 10(3):1–14.
7. Ernie HP, Ida H. Pemberian obat secara polifarmasi pada anak dan interaksi obat yang ditimbulkan. *Media Litbang Kesehatan*. 2007; XVII(1):26–9.
8. Mahmood I. Prediction of drug clearance in children from adults: A comparison of several allometric methods. *Br J Clin Pharmacol*. 2006; 61(5):545–57. <https://doi.org/10.1111/j.1365-2125.2006.02622.x> PMID: 16669848
9. Batchelor HK, Marriott JF. Paediatric pharmacokinetics: Key considerations. *Br J Clin Pharmacol*. 2015; 79(3):395–404. <https://doi.org/10.1111/bcp.12267> PMID: 25855821
10. Rashed AN, Wong ICK, Wilton L, Tomlin S, Neubert A. Drug Utilisation Patterns in Children Admitted to a Paediatric General Medical Ward in Five Countries. *Drugs—Real World Outcomes*. 2015; 2(4):397–410. <https://doi.org/10.1007/s40801-015-0049-y> PMID: 26690854
11. Sturkenboom MCJM, Verhamme KMC, Nicolosi A Murray ML, Neubert A, Caudri D, et al. Drug use in children: cohort study in three European countries. *BMJ*. 2008; 337:a2245 <https://doi.org/10.1136/bmj.a2245> PMID: 19029175
12. Vohora D, Dubey K, Najmi AK. Drug prescribing practices in paediatric department of a North Indian university teaching hospital *Academic Sciences Asian Journal of Pharmaceutical and Clinical Research*. 2012; 5:146–9.

13. Joseph F, Oladele O, Oludare O, Olatunde O. Drug prescribing pattern for under-fives in a paediatric clinic in south-western Nigeria. *Ethiop J Health Sci.* 2015; 25(1):73. <https://doi.org/10.4314/ejhs.v25i1.10> PMID: 25733787
14. Martha S, Thiruthopu N, Mateti U, Bairi R, Sivva D. Drug utilization pattern in South Indian pediatric population: A prospective study. *Perspect Clin Res [Internet].* 2014; 5(4):178. <https://doi.org/10.4103/2229-3485.140558> PMID: 25276628
15. Clavenna A, Berti A, Gualandi L, Rossi E, De Rosa M, Bonati M. Drug utilisation profile in the Italian paediatric population. *Eur J Pediatr.* 2009; 168(2):173–80. <https://doi.org/10.1007/s00431-008-0725-y> PMID: 18446366
16. Cazzato T, Pandolfini C, Campi R, Bonati M. Drug prescribing in out-patient children in Southern Italy. *Eur J Clin Pharmacol.* 2001; 57(8):611–6. <https://doi.org/10.1007/s002280100356> PMID: 11758641
17. Niclasen BVL. Changes in drug prescription over a decade in an Arctic child population. *Acta Paediatr Int J Paediatr.* 2006; 95(11):1456–60.
18. At Thobari J, Satria CD, Ridora Y, Watts E, Handley A, Samad S, et al. Antimicrobial use in an Indonesian community cohort 0–18 months of age. *Plos One.* 2019; 14(8):e0219097. <https://doi.org/10.1371/journal.pone.0219097> PMID: 31381611
19. Bines JE, At Thobari J, Satria CD, Handley A, Watts E, Cowley D, et al. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth. *N Engl J Med.* 2018; 378(8):719–30. <https://doi.org/10.1056/NEJMoa1706804> PMID: 29466164
20. Rasmussen F, Smedby B. Life table methods applied to use of medical care and of prescription drugs in early childhood. *J Epidemiol Community Health.* 1989; 43(2):140–6. <https://doi.org/10.1136/jech.43.2.140> PMID: 2592902
21. Thrane N, Sørensen HT. A one-year population-based study of drug prescriptions for Danish children. *Acta Paediatr Int J Paediatr.* 1999; 88:1131–6. <https://doi.org/10.1080/08035259950168216> PMID: 10565462
22. Jose J, Devassykutty D. Paediatric prescription analysis in a primary health care institution. *J Clin Diagnostic Res.* 2016; 10(11):FC05–FC08.
23. Sharma A, Shweta O. Assessment of drug prescription pattern in children: A descriptive study. *Natl J Physiol Pharm Pharmacol.* 2016; 6(1):74–80.
24. Van Riet-Nales DA, Schobben AFAM, Vromans H, Egberts TCG, Rademaker CMA. Safe and effective pharmacotherapy in infants and preschool children: Importance of formulation aspects. *Arch Dis Child.* 2016; 101(7):662–9. <https://doi.org/10.1136/archdischild-2015-308227> PMID: 26979250
25. Fangky SM, Deby M, Gayatri C. Kajian interaksi obat Pada pasien geriatri rawat inap. 2017; 6(3):2302–493.
26. Rahmawati F, Handayani R, Gosal V. Kajian Retrospektif Interaksi Obat di Rumah Sakit Pendidikan Dr. Sardjito Yogyakarta. *Maj Farm Indones.* 2006; 17(4):177–83.
27. Pandey A, Thakre S, Bhatkule P. Prescription analysis of pediatric outpatient practice in Nagpur city. *Indian J Community Med.* 2010; 35(1):70. <https://doi.org/10.4103/0970-0218.62564> PMID: 20606924
28. Cruz MJB, Dourado LFN, Bodevan EC, Andrade RA, Santos DF. Medication use among children 0–14 years old: Population baseline study. *J Pediatr (Rio J).* 2014; 90(6):608–15. <https://doi.org/10.1016/j.jped.2014.03.004> PMID: 24953722
29. Lubis IND, Lubis CP. Penanganan Demam pada Anak. *Sari Pediatr.* 2016; 12(6):409.
30. Kanabar DJ. A clinical and safety review of paracetamol and ibuprofen in children. *Inflammopharmacology.* 2017; 25(1):1–9. <https://doi.org/10.1007/s10787-016-0302-3> PMID: 28063133
31. Smith SM, Schroeder K, Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. *Cochrane Database Syst Rev.* 2008;(4):1–32. <https://doi.org/10.1002/14651858.CD001831.pub3> PMID: 18253996
32. Soedibyo S, Yulianto A, Wardhana. Profil Penggunaan Obat Batuk Pilek bebas pada pasien anak di bawah umur 6 tahun. *Sari Pediatr.* 2013; 14(6):398–404. <https://doi.org/10.1016/j.jamda.2013.01.014> PMID: 23419980
33. Rimsza ME. Unexpected Infant Deaths Associated With Use of Cough and Cold Medications: In Reply. *Pediatrics.* 2009; 123(2): e318–e322.
34. Lowry JA, Leeder JS. Over-the-Counter Medications: Update on Cough and Cold Preparations. *Pediatr Rev.* 2015; 36(7):286–98. <https://doi.org/10.1542/pir.36-7-286> PMID: 26133304
35. Briars LA. The Latest Update on Over-the-Counter Cough and Cold Product Use in Children. *J Pediatr Pharmacol Ther.* 2009; 14(3):127–31. <https://doi.org/10.5863/1551-6776-14.3.127> PMID: 23055900
36. Saraswat A, van Driel ML, De Sutter AI. Antihistamines for the common cold. *Cochrane Database Syst Rev.* 2011;(11):2–4.

37. Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children. *Drug Saf.* 2001; 24(2):119–47. <https://doi.org/10.2165/00002018-200124020-00003> PMID: 11235817
38. Shefrin AE, Goldman RD. Use of over-the-counter cough and cold medications in children. *Can Fam Physician.* 2009; 55(11):1081–3. PMID: 19910592
39. Schaefer MK, Shehab N, Cohen AL, Budnitz DS. Adverse Events From Cough and Cold Medications in Children. *Pediatrics.* 2008; 121(4):783–7. <https://doi.org/10.1542/peds.2007-3638> PMID: 18227192
40. Dart RC, Paul IM, Bond GR, Winston DC, Manoguerra AS, Palmer RB, et al. Pediatric Fatalities Associated With Over the Counter (Nonprescription) Cough and Cold Medications. *Ann Emerg Med.* 2009; 53(4):411–7. <https://doi.org/10.1016/j.annemergmed.2008.09.015> PMID: 19101060
41. Vorilhon P, Arpajou B, Vaillant Roussel H, Merlin É, Pereira B, Cabailot A. Efficacy of vitamin C for the prevention and treatment of upper respiratory tract infection. A meta-analysis in children. *Eur J Clin Pharmacol.* 2019; 75(3):303–11. <https://doi.org/10.1007/s00228-018-2601-7> PMID: 30465062
42. Rukmini S. Persepsi Ibu Tentang Klaim Kesehatan dan Manfaat Suplemen Serta Hubungannya dengan Konsumsi Suplemen. *Buletin Penelitian Sistem Kesehatan.* 2004; 7(2):130–43
43. Dalton MJT. Characteristics of pyridoxine overdose neuropathy syndrome. *Acta Neurol Scand.* 1987; 76(1):8–11. <https://doi.org/10.1111/j.1600-0404.1987.tb03536.x> PMID: 3630649
44. Pudjadi AH, Hegar B, Handryastuti S, Idris NS, Gandaputra EP. Diare akut. *Pedoman pelayanan medis.* 2009;58–61.
45. World Health Organization. *Integrated Management of Childhood Illness.* Geneva: World Health Organization; 2014.
46. Allen SJ, Martinez EG, Gregorio G V, Dans LF. Cochrane Review: Probiotics for treating acute infectious diarrhoea. *Evidence-Based Child Heal A Cochrane Rev J.* 2011; 6(6):1894–2021.
47. American Academy of Pediatrics. Practice parameter: The management of acute gastroenteritis in young children. *Pediatrics.* 1996; 97(3):424–36. PMID: 8604285



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

At Thobari, J; Satria, CD; Ridora, Y; Watts, E; Handley, A; Standish, J; Bachtiar, NS; Buttery, JP; Soenarto, Y; Bines, JE

Title:

Non-antibiotic medication use in an Indonesian community cohort 0-18 months of age.

Date:

2020

Citation:

At Thobari, J., Satria, C. D., Ridora, Y., Watts, E., Handley, A., Standish, J., Bachtiar, N. S., Buttery, J. P., Soenarto, Y. & Bines, J. E. (2020). Non-antibiotic medication use in an Indonesian community cohort 0-18 months of age.. PLoS One, 15 (11), pp.e0242410-. <https://doi.org/10.1371/journal.pone.0242410>.

Persistent Link:

<http://hdl.handle.net/11343/253050>

File Description:

Published version

License:

CC BY